Leinco Technologies, Inc.

09/03/2026

🔬 It’s time to get back to the bench! Our Annual Back to Bench Sale is officially live. Get your lab stocked and ready for a productive fall research season with 26% off select biological buffers, sheath fluid, and biosimilars. No promo code needed — discounts are applied automatically in your cart!

Shop Now: https://hubs.la/Q04wzkcc0

08/21/2026

Is background noise from trace endotoxin or incorrect kinetic timing corrupting your in vivo hyperinflammation data?

Measuring elevated circulating cytokines shows what is present, but it cannot distinguish a master driver from a bystander. To map true immunopathology across CAR-T CRS, sHLH/MAS, and sepsis models, researchers must move from correlative profiling to surgical, causal blockade.

In our latest technical article on LinkedIn Pulse, we break down:
- Why TNF-α + IL-6 vs. TNF-α + IFN-γ double blockade efficacy depends on storm etiology
- How kinetic timing governs therapeutic protection in acute challenge models
- How trace endotoxin (≤ 0.5 EU/mg) and Fc aggregates distort in vivo readouts
Read the full deep dive here:

https://hubs.la/Q04tL8rm0

Isolate true immunopathology in cytokine storm models. Learn how dual-pillar blockade and ultra-pure antibodies (

08/20/2026

We recently published a deep dive into what's new in Leinco's Emerging Infectious Disease (EID) antibody portfolio, and why the origin of a reagent matters for assay interpretability.

Here are some of the new patient-derived monoclonal antibody clones 𝗻𝗼𝘄 𝗮𝘃𝗮𝗶𝗹𝗮𝗯𝗹𝗲 across priority pathogens:

• 𝗠𝗮𝗿𝗯𝘂𝗿𝗴: 10-clone panel with structurally characterized RBS and wing-domain anchors
• 𝗘𝗯𝗼𝗹𝗮 (𝗘𝗕𝗢𝗩-𝟱𝟮𝟬): Broadly neutralizing base-region antibody cross-reactive against EBOV, BDBV, and SUDV
• 𝗕𝘂𝗻𝗱𝗶𝗯𝘂𝗴𝘆𝗼 (𝗕𝗗𝗕𝗩-𝟮𝟴𝟵): Cryo-EM characterized glycan-cap clone for epitope-resolved filovirus serology
• 𝗵𝗣𝗜𝗩𝟯: First commercial human mAb panel spanning pre-fusion F and HN glycoproteins
• 𝗩𝗘𝗘𝗩 (𝗵𝗩𝗘𝗘𝗩-𝟲𝟯): Cryo-EM resolved E2 domain B antibody with aerosol challenge protection data

Read our updated brochure for the science behind the portfolio and to view the complete catalog:

https://hubs.la/Q04qTcCT0

08/11/2026

⏰ An outbreak of an emerging infectious disease, like Hantavirus or Ebola Virus, can happen at any time.

That’s why 𝘄𝗲 𝗵𝗮𝘃𝗲 𝗲𝘅𝗽𝗮𝗻𝗱𝗲𝗱 𝗼𝘂𝗿 𝗘𝗺𝗲𝗿𝗴𝗶𝗻𝗴 𝗜𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝘂𝘀 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 (𝗘𝗜𝗗) 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝘆 𝗽𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 with new patient-derived monoclonal antibody clones across high-priority pathogens — including the deepest commercially available Marburg panel, the first commercial human mAb panel for hPIV3, and new coverage for VEEV and Ebola Virus.

Every antibody was sequenced from the B-cells of convalescent patients, preserving native immune-response specificity at protective epitopes that synthetic libraries cannot replicate.

👉🏻 Download our updated brochure to explore antibodies, antigens, matched pairs, and assay development services for 20+ pathogens.

https://hubs.la/Q04qT9rp0

08/05/2026

🧬The origin of a monoclonal antibody matters for assay development.

Leinco's recombinant human monoclonals are sequenced directly from B-cells of convalescent patients recovering from the respective infection. These antibodies reflect the epitopes the human immune system selected under natural disease pressure — including structurally conserved sites associated with protective immunity. Competitors largely rely on synthetic antibody libraries, which cannot capture that biological specificity.

Our updated emerging infectious disease (EID) portfolio includes structurally characterized clones with published cryo-EM epitope data across 𝗠𝗮𝗿𝗯𝘂𝗿𝗴 𝗚𝗣, 𝗘𝗯𝗼𝗹𝗮 𝗚𝗣, 𝗵𝗣𝗜𝗩𝟯 𝗙 𝗮𝗻𝗱 𝗛𝗡 𝗴𝗹𝘆𝗰𝗼𝗽𝗿𝗼𝘁𝗲𝗶𝗻, 𝗮𝗻𝗱 𝗩𝗘𝗘𝗩 𝗘𝟮 — giving researchers mechanistically interpretable reagents for neutralization assays, antigen QC, and epitope-resolved serology.

The collection has been cited in over 10,000 peer-reviewed publications across diagnostics, therapeutics, and vaccine research.

Download the updated brochure to review the full catalog ⬇️ https://hubs.la/Q04qTKTL0

08/03/2026

In this week’s spotlight, we’d like to recognize the groundbreaking work on revealing how lipid signaling regulates neutrophil responses to balance viral clearance and tissue immunopathology during chronic viral infections.
Read the Full Open-Access Article here:

https://hubs.la/Q04rHpSp0

This research article, "Sphingosine kinase 2 suppresses neutrophil responses to promote viral persistence while attenuating immune pathology," investigates the mechanisms underlying immune suppression during persistent Lymphocytic Choriomeningitis Virus (LCMV) infection. The researchers demonstrated that Sphingosine kinase 2 (SphK2) acts as a critical intrinsic regulator of neutrophils; SphK2-deficient neutrophils expand rapidly and display enhanced T-cell stimulatory activity with decreased immunosuppressive markers. To confirm the functional role of these hyper-reactive neutrophils in vivo, the team administered Leinco’s In Vivo Anti-Mouse Ly6G [Clone 1A8] for targeted cell depletion. Their findings reveal that while SphK2-mediated suppression of neutrophils allows persistent viral infection, it simultaneously shields host tissue from severe immunopathology, offering a crucial target for tuning innate immunity against chronic pathogens.

👇Featured products👇

• Anti-Mouse Ly6G [Clone 1A8]: https://hubs.la/Q04rHnfw0

Chronic viral infections often suppress immune cell functions, which helps restrict immune pathology but leads to viral persistence. However, the underlying ...

07/29/2026

The ADLM 2026 exhibit hall is officially open! 🎉

If you’re in Anaheim looking to elevate your diagnostic assays, stop by Booth #4342 to meet the Leinco team.

Come learn how our tailored custom buffer manufacturing and confirmed matched pair antibodies can help you streamline workflows, reduce batch-to-batch variability, and move your diagnostic products to market faster.

📍 Where to find us: Booth #4342
🌴 Location: Anaheim Convention Center

Stop by and say hello—we'd love to learn more about your current projects!

07/28/2026

When a new outbreak emerges, the reagent pipeline needs to be ready. 𝗪𝗲’𝘃𝗲 𝗮𝗱𝗱𝗲𝗱 𝗻𝗲𝘄 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝗶𝗲𝘀 𝘁𝗮𝗿𝗴𝗲𝘁𝗶𝗻𝗴 𝗽𝗿𝗶𝗼𝗿𝗶𝘁𝘆 𝗽𝗮𝘁𝗵𝗼𝗴𝗲𝗻𝘀 𝘁𝗼 𝗼𝘂𝗿 𝗼𝗳𝗳𝗲𝗿𝗶𝗻𝗴𝘀 to support development of rapid assays and effective countermeasures. 💪

Leinco's emerging infectious disease (EID) monoclonal antibody portfolio spans 20+ pathogens across:

• Hemorrhagic fevers
• Respiratory viruses
• Arboviruses
• Encephalitis viruses
• Other emerging threats

The collection is supported by matched antibody pairs, validated antigens, and complete assay development services — from sandwich ELISA and lateral flow screening to competition-based epitope mapping and antigen conformation QC.

➡️Download our updated brochure to 𝘀𝗲𝗲 𝘁𝗵𝗲 𝗻𝗲𝘄 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝗶𝗲𝘀 𝗻𝗼𝘄 𝗮𝘃𝗮𝗶𝗹𝗮𝗯𝗹𝗲: https://hubs.la/Q04qTvBl0

07/27/2026

Finding off-the-shelf antibody pairs and consistent buffers that meet your strict performance standards shouldn't hold back your diagnostic pipeline. 🧪

Our team at Leinco is heading to Anaheim for ADLM 2026 to help diagnostic developers and manufacturers eliminate raw material bottlenecks with:
- Custom Buffer Solutions: Formulated faster, more reliably, and built to scale.
- Matched Pair Antibodies: Confirmed to deliver accurate, reproducible IVD assay results.
- End-to-End Custom Antibody Services: Tailored support from initial antigen design through final validation.

Planning your time on the show floor? Lock in a dedicated 1-on-1 consultation with our attending team members to discuss your specific assay requirements.

👉 Schedule your meeting here:
https://hubs.la/Q04qT5rn0

See you in Anaheim at Booth #4342!

07/24/2026

Heading to ADLM 2026 in Anaheim next week? Let’s connect! ☀️

Diagnostic developers and manufacturers know that reproducible assays start with the right raw materials. Whether you're looking to scale up a custom buffer formulation or need matched-pair antibodies for your next IVD kit, the Leinco team is here to help you streamline performance from the start.

Our team will be on-site and booking 1-on-1 meetings to discuss your specific assay needs.

🗓️ Beat the show floor crowd—reserve a time today:
https://hubs.la/Q04qFvx_0

See you in Anaheim at Booth #4342!